CXCR4 antagonist 3

• UNSPSC Description:

  CXCR4 antagonist 3 (compound 12a) is a potent antagonist of CXCR4 with an IC50 of 11 nM. CXCR4 antagonist 3 is a congener of TIQ15. CXCR4 antagonist 3 demonstrates the best overall properties including CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. CXCR4 antagonist 3 has the potential for the research of human immunodeficiency virus[1].

• Target Antigen:

  CXCR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/cxcr4-antagonist-3.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NCCCCN([C@@H]1C2=NC=CC=C2CCC1)C[C@@H]3NCC4=C(C3)N=CC=C4

• Molecular Weight:

  365.52

• References & Citations:

  [1]Jecs E, et al. Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. J Med Chem. 2022;65(5):4058-4084.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2761009-43-0